Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 18/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034944 | 0.91 | TGFBR1 (0.53) | TGFBR1NPC1POLBRAB9AMAPK14 | |
| SCHEMBL4030130 | 0.87 | TGFBR1 (0.63) | TGFBR1MAPK14KDRPRKD1 | |
| SCHEMBL4029533 | 0.86 | NPC1 (0.53) | TGFBR1NPC1POLBRAB9AMAPK14 | |
| SCHEMBL4032549 | 0.84 | TGFBR1 (0.53) | TGFBR1NPC1POLBRAB9AMAPK14 | |
| SCHEMBL12270009 | 0.82 | NPC1 (0.62) | TGFBR1NPC1POLBRAB9AMAPK14 | |
| SCHEMBL4032092 | 0.81 | TGFBR1 (0.59) | TGFBR1MAPK14 | |
| SCHEMBL4032155 | 0.79 | TGFBR1 (0.44) | TGFBR1MAPK14 | |
| SCHEMBL4035598 | 0.79 | TGFBR1 (0.51) | TGFBR1NPC1POLBRAB9AMAPK14 | |
| SCHEMBL4032785 | 0.79 | TGFBR1 (0.62) | TGFBR1MAPK14KDRPRKD1 | |
| SCHEMBL4029464 | 0.78 | MAPK14 (0.60) | TGFBR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542994-B1 | NOVEL OXAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITOR | PFIZER PROD INC (US) | 2009-04-29 | — | — | EP | claimed |
| EP-1542994-B1 | NOVEL OXAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITOR | PFIZER PROD INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-7273936-B2 | Oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2007-09-25 | — | — | US | disclosed |
| EP-1542994-A1 | NOVEL TRIAZOLE AND OXAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITOR | Pfizer Products Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040110797-A1 | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
| WO-2004026863-A1 | NOVEL OXAZOLE AND THIAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110797-A1 | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | TGFBR1, TGFBR2, SMAD3 | TGFBR1 1/4885NPC1 3424/4885POLB 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.